Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company headquartered in Wilmette, IL. They are dedicated to developing proprietary therapeutics that aim to extend the lifespan or enhance the quality of life for cancer patients. With a focus on oncology, Monopar is building a robust drug development pipeline through the licensing and acquisition of late preclinical and clinical-stage oncology therapeutics, leveraging their scientific and clinical expertise to accelerate the development of their drug candidates.
Their pipeline includes camsirubicin, an analog of doxorubicin designed to minimize heart toxicity while maintaining its anticancer activity, targeting advanced soft tissue sarcoma. They are also developing MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers, and MNPR-202, an early-stage camsirubicin analog for various cancers. Monopar Therapeutics is driven by the increasing need for individualized therapies in oncology and the desire to improve patient outcomes in the face of the growing prevalence of cancer worldwide.
Generated from the website